S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
International Paper's 5% Yield Offers Big Value
The Strategic Gold Play You Haven't Heard About (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
The Strategic Gold Play You Haven't Heard About (Ad)
Low PE Growth Stocks: Unlocking Investment Opportunities
Why Ralph Lauren Should Be On Your Holiday Wishlist
The Strategic Gold Play You Haven't Heard About (Ad)
Stock market today: World shares are mostly lower, tracking a rates-driven tumble on Wall Street
3 Reliable Growing Dividends Near Rock-Bottom Prices
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
International Paper's 5% Yield Offers Big Value
The Strategic Gold Play You Haven't Heard About (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
The Strategic Gold Play You Haven't Heard About (Ad)
Low PE Growth Stocks: Unlocking Investment Opportunities
Why Ralph Lauren Should Be On Your Holiday Wishlist
The Strategic Gold Play You Haven't Heard About (Ad)
Stock market today: World shares are mostly lower, tracking a rates-driven tumble on Wall Street
3 Reliable Growing Dividends Near Rock-Bottom Prices
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
International Paper's 5% Yield Offers Big Value
The Strategic Gold Play You Haven't Heard About (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
The Strategic Gold Play You Haven't Heard About (Ad)
Low PE Growth Stocks: Unlocking Investment Opportunities
Why Ralph Lauren Should Be On Your Holiday Wishlist
The Strategic Gold Play You Haven't Heard About (Ad)
Stock market today: World shares are mostly lower, tracking a rates-driven tumble on Wall Street
3 Reliable Growing Dividends Near Rock-Bottom Prices
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
International Paper's 5% Yield Offers Big Value
The Strategic Gold Play You Haven't Heard About (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
The Strategic Gold Play You Haven't Heard About (Ad)
Low PE Growth Stocks: Unlocking Investment Opportunities
Why Ralph Lauren Should Be On Your Holiday Wishlist
The Strategic Gold Play You Haven't Heard About (Ad)
Stock market today: World shares are mostly lower, tracking a rates-driven tumble on Wall Street
3 Reliable Growing Dividends Near Rock-Bottom Prices
NASDAQ:BMEA

Biomea Fusion (BMEA) Stock Forecast, Price & News

$12.89
+0.18 (+1.42%)
(As of 10/3/2023 ET)
Compare
Today's Range
$12.32
▼
$13.19
50-Day Range
$12.71
▼
$22.25
52-Week Range
$6.04
▼
$43.69
Volume
360,413 shs
Average Volume
555,673 shs
Market Capitalization
$459.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$43.88
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Biomea Fusion MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.89 Rating Score
Upside/​Downside
240.4% Upside
$43.88 Price Target
Short Interest
Bearish
28.76% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.89mentions of Biomea Fusion in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($3.42) to ($3.76) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.82 out of 5 stars

Medical Sector

775th out of 966 stocks

Pharmaceutical Preparations Industry

360th out of 445 stocks

See Top Rated MarketRank™ Stocks Here

BMEA stock logo

About Biomea Fusion (NASDAQ:BMEA) Stock

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

BMEA Price History

BMEA Stock News Headlines

September 28, 2023 | markets.businessinsider.com
Positive Indicators Drive Buy Rating for Biomea Fusion: Promising T2D Treatment and Favorable Efficacy Outcomes
September 28, 2023 | finance.yahoo.com
Biomea Fusion Announces FDA and Health Canada Clearance of the Expansion Cohorts of the Ongoing COVALENT-111 Phase II Study
October 4, 2023 | Edge On The Street (Ad)
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
September 20, 2023 | seekingalpha.com
Navigating Biomea Fusion's Labyrinth: From Blood To Beta Cells
August 31, 2023 | finance.yahoo.com
Biomea Fusion Announces Appointment of Juan Pablo Frías, M.D. as Chief Medical Officer
August 1, 2023 | markets.businessinsider.com
H.C. Wainwright Remains a Buy on Biomea Fusion (BMEA)
July 31, 2023 | finance.yahoo.com
Biomea Fusion Reports Second Quarter 2023 Financial Results and Corporate Highlights
July 27, 2023 | msn.com
Scotiabank Initiates Coverage of Biomea Fusion (BMEA) with Sector Outperform Recommendation
October 4, 2023 | Wall Street Fundamentals (Ad)
Would Buffett Approve of This Growth Strategy?
Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.
July 25, 2023 | markets.businessinsider.com
14 Analysts Have This to Say About Biomea Fusion
July 24, 2023 | markets.businessinsider.com
Biomea Fusion (BMEA) Gets a Buy from H.C. Wainwright
July 24, 2023 | markets.businessinsider.com
Why Biomea Fusion Stock Is Falling Today?
July 24, 2023 | finance.yahoo.com
BMF-219 Induces Complete Responses in Target Acute Myeloid Leukemia (AML) Patient Population
July 16, 2023 | seekingalpha.com
Biomea Fusion: Potential Cure For Diabetes, Initiating With A Buy
July 13, 2023 | finance.yahoo.com
We Think Biomea Fusion (NASDAQ:BMEA) Needs To Drive Business Growth Carefully
July 6, 2023 | msn.com
Biomea Fusion (BMEA) Price Target Increased by 30.85% to 56.25
July 4, 2023 | theglobeandmail.com
BMEA ALERT: The Law Offices of Vincent Wong Investigate Biomea Fusion, Inc. for Potential Violations of Securities Laws
June 27, 2023 | msn.com
JP Morgan Maintains Biomea Fusion (BMEA) Overweight Recommendation
June 26, 2023 | businesswire.com
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Biomea Fusion, Inc. and Encourages Investors with Losses to Contact the Firm
June 26, 2023 | msn.com
Jefferies Reconsiders, BMEA Plummets after Sour Diabetes Drug Data
June 26, 2023 | markets.businessinsider.com
What 18 Analyst Ratings Have To Say About Biomea Fusion
June 26, 2023 | msn.com
Jefferies downgrades Biomea to hold amid new data on diabetes drug
June 26, 2023 | msn.com
Biomea Soars on Promising Phase 2 Data in Type 2 Diabetes
June 26, 2023 | markets.businessinsider.com
Piper Sandler Reaffirms Their Buy Rating on Biomea Fusion (BMEA)
June 26, 2023 | markets.businessinsider.com
Biomea Fusion Stock Is Trading Higher Today - Here's Why
June 23, 2023 | finance.yahoo.com
Biomea Fusion Presents Positive Clinical Data from the Initial Cohorts of the Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes Mellitus at the American Diabetes Association (ADA) 83rd Scientific Sessions; 100 mg Cohort 3 Demonstrated a 90% Response Rate and 70% Maintained or Improved Time in (Normal Glucose) Range, While Off-Treatment
June 20, 2023 | finance.yahoo.com
Biomea Fusion to Present Late Breaking Data from Ongoing Phase II Trial, COVALENT-111, Evaluating BMF-219 in Patients with Type 2 Diabetes at ADA 2023
See More Headlines
Receive BMEA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biomea Fusion and its competitors with MarketBeat's FREE daily newsletter.

BMEA Company Calendar

Last Earnings
7/31/2023
Today
10/04/2023
Next Earnings (Estimated)
11/06/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BMEA
CUSIP
N/A
CIK
1840439
Web
www.biomeafusion.com
Phone
650-980-9099
Fax
N/A
Employees
94
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$43.88
High Stock Price Forecast
$60.00
Low Stock Price Forecast
$22.00
Forecasted Upside/Downside
+240.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
9 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($3.32)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-81,830,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-74.75%
Return on Assets
-64.28%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
15.74
Quick Ratio
15.74

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.69 per share
Price / Book
3.49

Miscellaneous

Outstanding Shares
35,630,000
Free Float
26,271,000
Market Cap
$459.27 million
Optionable
Not Optionable
Beta
-1.06
10 Best Stocks to Own in 2023 Cover
10 Best Stocks to Own in 2023

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Thomas Andrew Butler (Age 42)
    Co-Founder, Chairman & CEO
    Comp: $921.14k
  • Mr. Ramses M. ErdtmannMr. Ramses M. Erdtmann (Age 60)
    Co-Founder, Pres, COO & Director
    Comp: $659.53k
  • Mr. Franco ValleMr. Franco Valle (Age 42)
    CFO & Principal Accounting Officer
    Comp: $651.77k
  • Mr. Heow Tan (Age 64)
    Chief Technology & Quality Officer
  • Ms. Naomi Cretcher
    Chief People Officer
  • Dr. Thorsten Kirschberg Ph.D. (Age 53)
    Exec. VP of Chemistry
  • Dr. Stephan Morris M.D.
    Chief Devel. Officer
  • Mr. Ravi Upasani
    Exec. VP of Intellectual Property
  • Dr. Juan Pablo Frias M.D.
    Chief Medical Officer & Member of Scientific Advisory Board

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













BMEA Stock - Frequently Asked Questions

Should I buy or sell Biomea Fusion stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biomea Fusion in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BMEA shares.
View BMEA analyst ratings or view top-rated stocks.

What is Biomea Fusion's stock price forecast for 2023?

9 Wall Street analysts have issued 12-month price targets for Biomea Fusion's shares. Their BMEA share price forecasts range from $22.00 to $60.00. On average, they predict the company's share price to reach $43.88 in the next year. This suggests a possible upside of 240.4% from the stock's current price.
View analysts price targets for BMEA or view top-rated stocks among Wall Street analysts.

How have BMEA shares performed in 2023?

Biomea Fusion's stock was trading at $8.43 at the beginning of the year. Since then, BMEA stock has increased by 52.9% and is now trading at $12.89.
View the best growth stocks for 2023 here.

When is Biomea Fusion's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our BMEA earnings forecast.

How were Biomea Fusion's earnings last quarter?

Biomea Fusion, Inc. (NASDAQ:BMEA) posted its quarterly earnings results on Monday, July, 31st. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.86) by $0.16.

What ETF holds Biomea Fusion's stock ?

Invesco Dorsey Wright Healthcare Momentum ETF holds 113,300 shares of BMEA stock, representing 1.44% of its portfolio.

When did Biomea Fusion IPO?

(BMEA) raised $120 million in an initial public offering on Friday, April 16th 2021. The company issued 7,500,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies and Piper Sandler served as the underwriters for the IPO.

What is Biomea Fusion's stock symbol?

Biomea Fusion trades on the NASDAQ under the ticker symbol "BMEA."

How do I buy shares of Biomea Fusion?

Shares of BMEA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biomea Fusion's stock price today?

One share of BMEA stock can currently be purchased for approximately $12.89.

How much money does Biomea Fusion make?

Biomea Fusion (NASDAQ:BMEA) has a market capitalization of $459.27 million. The company earns $-81,830,000.00 in net income (profit) each year or ($3.32) on an earnings per share basis.

How can I contact Biomea Fusion?

The official website for the company is www.biomeafusion.com. The company can be reached via phone at 650-980-9099 or via email at vsandwick@biomeafusion.com.

This page (NASDAQ:BMEA) was last updated on 10/4/2023 by MarketBeat.com Staff

My Account -